Media Newsroom of

Antisense Therapeutics Limited

6 Wallace Avenue
Toorak, Victoria 3142

First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular Dystrophy

 Antisense Therapeutics (ASX:ANP) today announced dosing of the first patient in a Phase II clinical trial of its immunomodulatory therapy, ATL1102, in patients with Duchenne Muscular Dystrophy (DMD). Commencement of the trial represents an important development milestone for the Company…

Approval Received for Phase II Trial of ATL1102 in Duchenne Muscular Dystrophy

Antisense Therapeutics ("ANP” or the “Company”) is pleased to advise that the Company has received approval from the Royal Children’s Hospital (RCH), Melbourne Human Research Ethics Committee, to undertake a Phase II clinical trial of its immunomodulatory therapy, ATL1102, in…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login